The data will be presented at the ISIRV-WHO virtual conference in 2021
Waltham, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) – Adagio Therapeutics, Inc. (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company specializing in antibody solutions for the treatment of infectious diseases with epidemic potential The discovery, development and commercialization of the program, today announced the discovery of new in vitro data research, showing that its monoclonal antibody (mAb) ADG20 is against the diversified circulating SARS-CoV-2 variants (including the newly emerging Lambda and Mu variants). And activity. It is worth noting that the research findings show that ADG20 shows strong in vitro neutralizing activity for all tested SARS-CoV-2 variants, including those with reduced sensitivity to those supplied under an emergency use authorization (EUA) or in a later stage of development. mAb product. These data will be displayed in the poster session of the 2021 ISIRV-WHO virtual conference to be held from October 19 to 21, 2021. In addition, Adagio will also publish a special poster highlighting the recently announced data of the company’s ongoing ADG20 Phase 1 trial among healthy participants.
Dr. Laura Walker, Co-founder and Scientific Director of Adagio, said: “These new variant data further highlight the potential of ADG20 to solve the current COVID-19 outbreak and other future outbreaks similar to SARS viruses. We designed this mAb specifically The product has a broad and effective anti-chemical activity and prolongs its potential protective half-life window, and these key functions may make this product different from EUA supply or other treatments currently being developed. With the global phase 2/3 Prevention and treatment trials are ongoing, and we look forward to continuing to evaluate ADG20 to assess its possible important role in the treatment of coronavirus disease 2019. ADG20 is administered as a single intramuscular injection in clinical trials and is designed to be used in a preventive environment It provides protection for up to one year and is exploring as a treatment and/or vaccine supplement for high-risk patients, including individuals with weakened immune functions.”
In addition to the Phase 1 healthy participant trial, Adagio is currently conducting two ongoing global Phase 2/3 trials, a treatment trial (STAMP) and a prevention trial (EVADE). The company expects to submit an EUA application for ADG20 to the U.S. Food and Drug Administration in the first quarter of 2022.
Presentation details
Poster title:(130) ADG20, as a monoclonal antibody with an extended half-life, is used to prevent and treat the 2019 coronavirus disease. It can neutralize SARS-CoV-2 variants widely and effectively in vitro
Poster title:(131) To evaluate the safety, tolerability and pharmacokinetics of ADG20, which is a half-life-prolonging monoclonal antibody (mAb) for the prevention and treatment of coronavirus disease 2019: preliminary randomized phase 1 study analyze
about ADG20
ADG20 is a monoclonal antibody against the spike protein of SARS-CoV-2 and related coronaviruses. It is currently being developed to prevent and treat the 2019 coronavirus disease caused by SARS-CoV-2. The design and engineering of ADG20 aims to achieve high-efficiency and extensive neutralization of SARS-CoV-2 and other type 1 type B coronavirus branch B through highly conserved epitopes in the field of target receptor binding. ADG20 shows effective neutralizing activity against the original SARS-CoV-2 strain and all known variants of interest in vitro. ADG20 may affect virus replication and subsequent diseases through a variety of mechanisms of action, including directly preventing the virus from entering host cells (neutralization), and eliminating infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered through a single intramuscular injection and is engineered to have a long half-life, aiming to provide fast and long-lasting protection. Adagio is advancing ADG20 through multiple clinical trials around the world.
about Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focusing on research, development and commercialization of infectious disease antibody solutions with epidemic potential. The company’s antibody product portfolio is optimized using Adimab’s industry-leading antibody engineering capabilities to provide patients and clinicians with a powerful combination of efficacy, breadth, long-lasting protection (through prolonged half-life), manufacturability and affordability. Adagio’s SARS-CoV-2 antibody portfolio includes a number of non-competitive broadly neutralizing antibodies led by ADG20. Adagio has secured manufacturing capabilities to produce ADG20 with third-party contract manufacturers to support the completion of clinical trials and preliminary commercial releases, and to ensure widespread supply to people around the world. For more information, please visit www.adagiotx.com.
Forward-looking statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Words such as “expect”, “believe”, “expect”, “intend”, “forecast” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements about the timing, progress and results of ADG20 preclinical studies and clinical trials, including the time of our planned emergency use authorization submission, the start, completion and related preparations of studies or trials, the provision of trial results and our R&D planning period; our ability to obtain and maintain regulatory approvals for our product candidates; our ability to identify patients with diseases treated by our candidate products and include these patients in our clinical trials; our manufacturing capabilities and strategies ; And our ability to successfully commercialize candidate products. We may not actually be able to achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not rely too much on our forward-looking statements. successfully commercialize our product candidates. These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from those described or implied by the forward-looking statements, including but not limited to Adagio as of June 30, 2021 The quarterly report on Form 10-Q for the last quarter and Adagio will submit to the SEC the risks described under the heading “Risk Factors” in the future. This risk may be amplified by the impact of the COVID-19 outbreak. The forward-looking statements contained in this press release are as of now, and Adagio assumes no obligation to update such information unless required by applicable law.
contact person:
Media Contact:
Dan Budwick，1AB |
e-mail:[email protected]
Investor Contact:
Monique Allaire | THRUST Strategic Communications
[email protected]
